Hongbing Huang

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Amgen Inc.. Active years: 2013-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongbing Huang. Retrieved from https://idiyas.com/inventor/hongbing-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 13.2

ph-index = 4

Forward Citations = 185(Granted Patents)

Location History:

Lexington, MA (US) (2013 - 2016)
Brighton, MA (US) (2016 - 2017)
Bellarie, TX (US) (2017)

Company Filing History:

6 out of 2,069

Amgen Inc.

patents

Years Active: 2013-2017

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9776995 - Bicyclic sulfonamide compounds as sodium channel inhibitors (2017-10-03),

2. 9663508 - Biaryl acyl-sulfonamide compounds as sodium channel inhibitors (2017-05-30),

3. 9458152 - Bicyclic sulfonamide compounds as sodium channel inhibitors (2016-10-04),

4. 9340549 - Oxazolidinone compounds and derivatives thereof (2016-05-17),

5. 9212182 - Bicyclic sulfonamide compounds as sodium channel inhibitors (2015-12-15),

6. 8426447 - Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use (2013-04-23),

Title: Innovations of Hongbing Huang

Introduction

Hongbing Huang is a notable inventor based in Lexington, MA, who has made significant contributions to the field of pharmaceutical sciences. With a total of six patents to his name, Huang's work primarily focuses on developing compounds that target sodium channels, which are crucial in the treatment of various pain disorders.

Latest Patents

Huang's latest patents include innovative compounds such as bicyclic sulfonamide compounds that act as sodium channel inhibitors. These compounds are designed to inhibit voltage-gated sodium channels, particularly Nav1.7, and are useful in treating diseases associated with pain disorders. Additionally, he has developed biaryl acyl-sulfonamide compounds that serve a similar purpose, providing pharmaceutical compositions that can be utilized in medical treatments.

Career Highlights

Huang is currently employed at Amgen Inc., a leading biotechnology company known for its focus on innovative therapies. His work at Amgen has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Huang collaborates with esteemed colleagues such as Matthew M Weiss and Erin F DiMauro, enhancing the research efforts within his team and contributing to the advancement of medical science.

Conclusion

Hongbing Huang's innovative work in developing sodium channel inhibitors showcases his dedication to improving treatments for pain disorders. His contributions to the field are significant and continue to impact the pharmaceutical landscape positively.

Profile summary based on public USPTO records.